Atacicept
IgA Nephropathy (IgAN)
Key Facts
About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotech focused on developing transformative treatments for B-cell and plasma cell-driven autoimmune diseases. Its core achievement is the successful Phase 3 ORIGIN 3 trial of atacicept in IgA nephropathy (IgAN), meeting its primary endpoint in June 2025, which sets the stage for a potential first-in-class therapy. The company's strategy leverages a deep understanding of B-cell biology to selectively target pathogenic drivers, with a lean operational model aimed at efficiently advancing its pipeline toward commercialization and addressing high unmet medical needs.
View full company profileAbout Vera Therapeutics
Vera Therapeutics is a clinical-stage biotech focused on developing transformative treatments for B-cell and plasma cell-driven autoimmune diseases. Its core achievement is the successful Phase 3 ORIGIN 3 trial of atacicept in IgA nephropathy (IgAN), meeting its primary endpoint in June 2025, which sets the stage for a potential first-in-class therapy. The company's strategy leverages a deep understanding of B-cell biology to selectively target pathogenic drivers, with a lean operational model aimed at efficiently advancing its pipeline toward commercialization and addressing high unmet medical needs.
View full company profileTherapeutic Areas
Other IgA Nephropathy (IgAN) Drugs
| Drug | Company | Phase |
|---|---|---|
| R1065 | Harbour BioMed | Discovery |
| TARPEYO (Nefecon) | Calliditas Therapeutics | Approved |
| TARPEYO (Nefecon) OLE | Calliditas Therapeutics | Phase 3 |
| KP104 | Kira Pharmaceuticals | Phase 2 |
| IFX-301 | Infinimmune | Preclinical |
| FILSPARI (sparsentan) | Travere Therapeutics | Approved |
| Telitacicept | Vor Biopharma | BLA Submitted |